Junctional adhesion molecule 3 is a potential therapeutic target for small cell lung carcinoma.

导出 LinkOut

翻译打印收藏纠错

作者： Miki,Yamaguchi ^[1] ; Sachie,Hirai ^[1] ; Masashi,Idogawa ^[2] ; Toshiyuki,Sumi ^[3] ; Hiroaki,Uchida ^[4] ; Naoki,Fujitani ^[5] ; Motoko,Takahashi ^[5] ; Yuji,Sakuma ^[6]

作者单位： Department of Molecular Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. ^[1] Department of Medical Genome Sciences, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. ^[2] Department of Molecular Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, Japan. ^[3] Project Division of Cancer Biomolecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ^[4] Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan. ^[5] Department of Molecular Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. Electronic address: sakuma@sapmed.ac.jp. ^[6]

关键词 Antibody–drug conjugate (ADC)Junctional adhesion molecule 3 (JAM3)Small cell lung cancer (SCLC)

主题词人类(Humans);小细胞肺癌(Small Cell Lung Carcinoma);肺肿瘤(Lung Neoplasms);RNA, 信使(RNA, Messenger)

DOI 10.1016/j.yexcr.2023.113570

PMID 36990421

发布时间 2023-04-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交